Skip to main content

Table 1 Patient characteristics

From: Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

 

Baseline

After 52-week use of CT-P13

p value

Age (years)

69.5 (63–77)

  

Gender (male/female), n (%)

7 (25) / 21 (75)

  

Body weight (kg)

51.9 (46.6–58.4)

  

Disease duration (years)

18 (12.5–27)

  

ACPA positive, %

89

  

RF positive, %

81

  

Steinbrocker class, (1/2/3/4)

7/ 9/ 12/ 0

  

Use of MTX, n (%)

28 (100)

28 (100)

 

Dose of MTX (mg/week)

6 (4–8)

6 (4–8)

 

Use of corticosteroids, n (%)

14 (50)

14 (50)

 

Dose of corticosteroids (mg/day)

2.5 (2.5–5)

2.5 (2.5–5)

0.33

Prior IFX treatment duration (months)

109 (93.5–131.5)

  

Prior IFX treatment dose (mg/kg)

6.5 (4.5–8.9)

  

Prior IFX treatment interval (weeks)

8 (8–9)

  

ESR (mm/h)

22.5 (15.3–35.8)

18.5 (8.8–29.8)

0.06

CRP (mg/dL)

0.1 (0.06–0.8)

0.2 (0.07–0.8)

0.93

MMP-3 (ng/ml)

80.2 (39.1–138.7)

66.8 (39.0–106.2)

0.3

DAS28

2.9 (2.3–3.2)

2.7 (1.9–3.1)

0.23

  1. The data are median (interquartile range, Q1/4–Q3/4) or number (percentage)
  2. ACPA anti-CCP antibody, CRP C-reactive protein, DAS28 disease activity score assessing 28 joints, ESR erythrocyte sedimentation rate, IFX infliximab, MMP-3 matrix metalloproteinase-3, MTX methotrexate, RF rheumatoid factor